A Case of Multiple Primary Pulmonary Neuroendocrine Carcinoma
with EML4-ALK Fusion Gene Positive.
10.3779/j.issn.1009-3419.2025.102.10
- Author:
Yin ZHANG
1
;
Yue HOU
1
;
Tianming ZHANG
1
;
Hong WANG
1
Author Information
1. Department of Pulmonary and Critical Care Medicine, Lanzhou University Second Hospital, Lanzhou 730030, China.
- Publication Type:English Abstract
- Keywords:
ALK mutation;
Large cell neuroendocrine carcinoma of the lung;
Lung neoplasms;
Targeted therapy
- MeSH:
Humans;
Oncogene Proteins, Fusion/metabolism*;
Female;
Lung Neoplasms/enzymology*;
Carcinoma, Neuroendocrine/pathology*;
Middle Aged
- From:
Chinese Journal of Lung Cancer
2025;28(3):230-236
- CountryChina
- Language:Chinese
-
Abstract:
Neuroendocrine carcinoma (NEC), a subtype of neuroendocrine tumors with high proliferative activity, is characterized by strong invasiveness and poor prognosis. This article reports a previously healthy female non-smoker who developed NEC occurring sequentially in different lobes of both lungs. The lesions were pathologically diagnosed by hematoxylin-eosin (HE) staining as large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC), respectively. Next-generation sequencing (NGS) performed on both lesions revealed the presence of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion mutations in both lesions. Notably, the patient achieved a significant therapeutic response to ALK-tyrosine kinase inhibitors (TKIs) targeted therapy.
.
